Matches in SemOpenAlex for { <https://semopenalex.org/work/W2259383959> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2259383959 endingPage "iv266" @default.
- W2259383959 startingPage "iv266" @default.
- W2259383959 abstract "ABSTRACT Aim: In castration- and docetaxel-resistant prostate cancer cells, sorafenib has been shown to cause apoptosis through downregulation of myeloid cell leukemia-1, phosphorylation of Akt and inhibition of androgen receptor (AR) expression as well as of its constitutively active, C-terminally truncated AR lacking the AR-ligand binding domain. We aimed to evaluate whether thus sorafenib may stabilize disease after failure of docetaxel in castration-resistant prostate cancer patients. Methods: In our phase 2, double-blind, placebo-controlled trial, 51 men with castration-resistant, docetaxel-refractory prostate cancer were randomly assigned to receive sorafenib 400mg twice daily or best supportive care for 12 weeks. The primary endpoint was the rate of patients who experienced stable disease (or partial response) for at least 12 weeks of treatment. Secondary efficacy variables were response rate according to RECIST criteria, progression-free survival and evaluation of biomarkers in serum. Results: In 8 (partial response: 2; stable disease: 6) out of 24 patients in the sorafenib group (33.3%) but only 2 (stable disease: 2) out of 27 patients in the placebo group (7.4%) tumor stabilization was observed (p = 0.024). Median progression-free survival and overall survival was in favour of the sorafenib group compared with placebo (100 versus 89 days; p = 0.019 and 369 versus 249 days; p= n.s.). In accordance with clinical results, serum values of M65, a prognostic biomarker of tumor progression, stabilized during sorafenib with a maximum effect at week eight (+5 %) while increasing with placebo (+41%). Rates of fatigue, diarrhea, appetite loss, hand-foot syndrome and hypertension were higher with sorafenib but well manageable. Conclusions: For the first time, sorafenib showed significant antitumor activity in patients with metastatic CRPC in the post-docetaxel setting. With activity against C-terminally truncated, constitutively active AR variants assumed to be present in abiraterone-resistant tumor cell clones it may be an option for new treatment sequences and combinations in future. Disclosure: G. Kramer: honorary fees from Advisory Boards: Amgen, Astellas, Bayer, Janssen, Ipsen, Sanofi-Aventis, Takeda, Roche, GSK, Novartis and research grant by Sanofi-Aventis;S.F. Shariat: Honorary fees for advisory boards for Janssen, Ipsen and Astellas;W. Loidl: Honorary fees for advisory boards for Sanofi-Aventis, GSK, Janssen, Roche, Novartis, Takeda, Astellas, Amgen, Ipsen, Bayer. All other authors have declared no conflicts of interest." @default.
- W2259383959 created "2016-06-24" @default.
- W2259383959 creator A5006782095 @default.
- W2259383959 creator A5031897532 @default.
- W2259383959 creator A5039804377 @default.
- W2259383959 creator A5061666212 @default.
- W2259383959 creator A5079977409 @default.
- W2259383959 date "2014-09-01" @default.
- W2259383959 modified "2023-10-16" @default.
- W2259383959 title "Multicenter, Randomized, Double-Blind Phase Ii Study of Sorafenib Compared to Placebo with Best Supportive Care After Failure of Docetaxel in Metastatic Castration-Resistant Prostate Cancer" @default.
- W2259383959 doi "https://doi.org/10.1093/annonc/mdu336.21" @default.
- W2259383959 hasPublicationYear "2014" @default.
- W2259383959 type Work @default.
- W2259383959 sameAs 2259383959 @default.
- W2259383959 citedByCount "0" @default.
- W2259383959 crossrefType "journal-article" @default.
- W2259383959 hasAuthorship W2259383959A5006782095 @default.
- W2259383959 hasAuthorship W2259383959A5031897532 @default.
- W2259383959 hasAuthorship W2259383959A5039804377 @default.
- W2259383959 hasAuthorship W2259383959A5061666212 @default.
- W2259383959 hasAuthorship W2259383959A5079977409 @default.
- W2259383959 hasConcept C121608353 @default.
- W2259383959 hasConcept C126322002 @default.
- W2259383959 hasConcept C142724271 @default.
- W2259383959 hasConcept C143998085 @default.
- W2259383959 hasConcept C204787440 @default.
- W2259383959 hasConcept C27081682 @default.
- W2259383959 hasConcept C2778019345 @default.
- W2259383959 hasConcept C2778695046 @default.
- W2259383959 hasConcept C2780192828 @default.
- W2259383959 hasConcept C2781190966 @default.
- W2259383959 hasConcept C71924100 @default.
- W2259383959 hasConceptScore W2259383959C121608353 @default.
- W2259383959 hasConceptScore W2259383959C126322002 @default.
- W2259383959 hasConceptScore W2259383959C142724271 @default.
- W2259383959 hasConceptScore W2259383959C143998085 @default.
- W2259383959 hasConceptScore W2259383959C204787440 @default.
- W2259383959 hasConceptScore W2259383959C27081682 @default.
- W2259383959 hasConceptScore W2259383959C2778019345 @default.
- W2259383959 hasConceptScore W2259383959C2778695046 @default.
- W2259383959 hasConceptScore W2259383959C2780192828 @default.
- W2259383959 hasConceptScore W2259383959C2781190966 @default.
- W2259383959 hasConceptScore W2259383959C71924100 @default.
- W2259383959 hasLocation W22593839591 @default.
- W2259383959 hasOpenAccess W2259383959 @default.
- W2259383959 hasPrimaryLocation W22593839591 @default.
- W2259383959 hasRelatedWork W1898921923 @default.
- W2259383959 hasRelatedWork W2010765098 @default.
- W2259383959 hasRelatedWork W2060708716 @default.
- W2259383959 hasRelatedWork W2094570582 @default.
- W2259383959 hasRelatedWork W2588988563 @default.
- W2259383959 hasRelatedWork W2735900144 @default.
- W2259383959 hasRelatedWork W2770702948 @default.
- W2259383959 hasRelatedWork W3023947295 @default.
- W2259383959 hasRelatedWork W3155233782 @default.
- W2259383959 hasRelatedWork W4226303148 @default.
- W2259383959 hasVolume "25" @default.
- W2259383959 isParatext "false" @default.
- W2259383959 isRetracted "false" @default.
- W2259383959 magId "2259383959" @default.
- W2259383959 workType "article" @default.